FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcriptionXuemei Li, Lei Gao, Bofang Wang, Jike Hu, Yang Yu, Baohong Gu, Lin Xiang, Xiaomei Li, Haiyuan Li, Tao Zhang, Yunpeng Wang, Chenhui Ma, Jiahong Dong, Jianrong Lu, Alexandra LucasSee the full list of authors
25 July 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa RosenblattSee the full list of authors
25 July 2024
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancersNoboru Yamamoto, Shigehisa Kitano, Takafumi Koyama, Masafumi Ikeda, Hidenori Mizugaki, Takatsugu Narikiyo, Yuki Yamaguchi, Takaaki Ishida, Ryoko Takubo, Chika Ogami, Mayuko Sekiya, Yuki Nakagawa, Yasutoshi Kuboki
24 July 2024
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancerNiels E Wondergem, Iris H C Miedema, Rieneke van de Ven, Gerben J C Zwezerijnen, Pim de Graaf, K Hakki Karagozoglu, Jan-Jaap Hendrickx, Simone E J Eerenstein, Rolf J Bun, Dorien C Mulder, Jens Voortman, Ronald Boellaard, Albert D Windhorst, J Pascal Hagers, Laura A N PeferoenSee the full list of authors
22 July 2024
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastasesChandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Jason LaPorte, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha, Prajna Guha, Steven C KatzSee the full list of authors
22 July 2024
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitorsPatrick Tiongco Magahis, Tara Corso, Pamela Livingstone, Erika Tom, Amitabh Srivastava, Michael Postow, David Faleck
20 July 2024
Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatmentYoonjeong Choi, Seong A Kim, Hanul Jung, Eunhae Kim, Yoon Kyoung Kim, Seohyun Kim, Jaehyun Kim, Yeji Lee, Min Kyoung Jo, Jiwan Woo, Yakdol Cho, Dongjoo Lee, Hongyoon Choi, Cherlhyun Jeong, Gi-Hoon NamSee the full list of authors
15 July 2024
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary studyGaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, Najeeb Halabi, Eliane Mery-Lamarche, Noemie Thebault, Clara-Maria Scarlata, Marie Michelas, Anne-Sophie Navarro, Gwenaël Ferron, Fabrice Lecuru, Patrice Mathevet, Jonathan Khalifa, Maha Ayyoub, Arash RafiiSee the full list of authors
15 July 2024
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen speciesMan Zhu, Wenjun Tang, Xiaoyu Tang, Zeren Zhu, Yina Jiang, Ammar Sarwar, Hongmei Zhang, Dake Chu, Zixi Zhang, Yanmin Zhang
14 July 2024
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitorsJuan Chen, Jia-Si Liu, Jun-Yan Liu, Lei She, Ting Zou, Fan Yang, Xiang-Ping Li, Zhan Wang, Zhaoqian Liu
11 July 2024